Study of Correlation Between SFRP-1 and SFRP-2 Hypermethylation With Relapse, Complete Remission, Genetic Mutations of FLT3-ITD and NPM1 and Immunophenotypes of Leukemic Cells in Patients With De Novo Acute Myeloblastic Leukemia

Ali Ghasemi, Fatemeh Nadali, Bahram Chahardouli, Nasrin Alizad Ghandforosh, Ardeshir Ghavam Zadeh, Shahrbano Rostami

Abstract


Background: Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic stem cells that is associated with the infiltration of blasts in the peripheral blood and bone marrow. In recent years, the role of epigenetic abnormalities such as promoter methylation of tumor suppressor genes, including secreted frizzled related proteins (SFRPs) family genes, has been shown in the pathogenesis of cancers. This study evaluates the correlation between SFRP-1 and SFRP-2 hypermethylation with genetic mutations of FLT3-ITD, NPM1 and immunophenotypes of leukemic cells.

Methods: In peripheral blood from 43 patients with de novo AML, isolated DNA was treated with sodium bisulphite and analyzed by methylation-specific polymerase chain reaction (MSP). Fisher exact test and SPSS 21 were used for statistical data analysis.

Results: SFRP-1 hypermethylation had significant association with CD34 (P = 0/045) and CD14 (P = 0/046) expression. There was no difference in the incidence of genetic mutations of FLT3-ITD and NPM1 between patients with and without SFRP hypermethylation.

Conclusion: Based on these results, hypermethylation of SFRP-1 is associated with increased expression of CD34 and CD14 antigenes. However, further studies on a large group of patients are necessary to confirm our findings.




J Hematol. 2014;3(2):34-42
doi: http://dx.doi.org/10.14740/jh154w


Keywords


Acute myeloblastic leukemia; DNA methylation; Genetic mutation; Immunophenotype

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Hematology, quarterly, ISSN 1927-1212 (print), 1927-1220 (online), published by Elmer Press Inc.               
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC BY-NC 4.0)



This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.thejh.org    editorial contact: editor@thejh.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada
 

© Elmer Press Inc. All Rights Reserved.

IMPORTANT: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!